Gynecologic Cancers: Case 2 - Episode 4
Dr. Monk says that Stephanie an ideal candidate for bevacizumab. When she progresses after first-line treatment of metastatic disease (platinum doublet +/- bevacizumab), additional therapy is of unproven benefit. The highest response rate is with weekly nanoparticle albumin-bound (nab)-paclitaxel in this setting, according to GOG phase II studies. Immunotherapy is an emerging strategy.
CASE 2: Cervical Cancer
Stephanie M. is a 48-year-old Caucasian mother of 2 children who works as a dental hygienist.
She presented to her PCP in May 2012 with vaginal discharge and pain during intercourse. Prior medical history was notable for smoking (quit 3 years ago) and well-controlled hypertension. Patient had completed only sporadic cervical screening for the past 10 years.
In September 2014, she presented with worsening abdominal pain and fatigue. CT scan showed diffuse pelvic and aortic adenopathy consistent with disease recurrence. Her renal and hepatic function were adequate.